CD28 and Hodgkins lymphoma: To evaluate the effector functions of newly generated CD28-based second-generation anti-CD30 CAR-T cells differing only for scFv, we initially performed three different in vitro assays in order to assess their killing profile, proliferation rate, and cytokine release after encountering the CD30 target antigen expressed on the HD-LM2 Hodgkin’s Lymphoma cell line.